Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but sever...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | Visualized Cancer Medicine |
| Subjects: | |
| Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206524186722304 |
|---|---|
| author | Wu Helena T. Hsu Vanessa Win Shwe Xing Yan |
| author_facet | Wu Helena T. Hsu Vanessa Win Shwe Xing Yan |
| author_sort | Wu Helena T. |
| collection | DOAJ |
| description | Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but severe immunotherapy-related cardiotoxicities. This review examines various immunotherapy types, such as immune checkpoint inhibitors, adoptive T-cell therapies, and cancer vaccines, highlighting their cardiovascular risks. Cardiotoxicities can lead to life-threatening complications, especially in high-risk patients. Early detection and prevention are crucial, with comprehensive cardiovascular assessments and routine biomarker monitoring playing a central role. With immunotherapies becoming more prevalent, this review calls for stronger evidence-based guidelines to manage and prevent these cardiovascular complications, ensuring that patients can benefit from life-saving immunotherapies without jeopardizing cardiovascular health. |
| format | Article |
| id | doaj-art-e5e6474660834276ab38cbd1c52858fa |
| institution | Kabale University |
| issn | 2740-4218 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | Visualized Cancer Medicine |
| spelling | doaj-art-e5e6474660834276ab38cbd1c52858fa2025-02-07T08:34:17ZengEDP SciencesVisualized Cancer Medicine2740-42182025-01-016110.1051/vcm/2025003vcm20240019Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatableWu Helena T.0https://orcid.org/0009-0005-2193-1829Hsu Vanessa1Win Shwe2Xing Yan3City of Hope Comprehensive Cancer CenterCity of Hope Comprehensive Cancer CenterCity of Hope Comprehensive Cancer CenterCity of Hope Comprehensive Cancer CenterAnti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but severe immunotherapy-related cardiotoxicities. This review examines various immunotherapy types, such as immune checkpoint inhibitors, adoptive T-cell therapies, and cancer vaccines, highlighting their cardiovascular risks. Cardiotoxicities can lead to life-threatening complications, especially in high-risk patients. Early detection and prevention are crucial, with comprehensive cardiovascular assessments and routine biomarker monitoring playing a central role. With immunotherapies becoming more prevalent, this review calls for stronger evidence-based guidelines to manage and prevent these cardiovascular complications, ensuring that patients can benefit from life-saving immunotherapies without jeopardizing cardiovascular health.https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.htmlimmunotherapycardiotoxicityimmune checkpoint inhibitorscancer immunotherapymelanoma |
| spellingShingle | Wu Helena T. Hsu Vanessa Win Shwe Xing Yan Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable Visualized Cancer Medicine immunotherapy cardiotoxicity immune checkpoint inhibitors cancer immunotherapy melanoma |
| title | Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable |
| title_full | Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable |
| title_fullStr | Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable |
| title_full_unstemmed | Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable |
| title_short | Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable |
| title_sort | anti cancer immunotherapy related cardiotoxicity preventable and treatable |
| topic | immunotherapy cardiotoxicity immune checkpoint inhibitors cancer immunotherapy melanoma |
| url | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.html |
| work_keys_str_mv | AT wuhelenat anticancerimmunotherapyrelatedcardiotoxicitypreventableandtreatable AT hsuvanessa anticancerimmunotherapyrelatedcardiotoxicitypreventableandtreatable AT winshwe anticancerimmunotherapyrelatedcardiotoxicitypreventableandtreatable AT xingyan anticancerimmunotherapyrelatedcardiotoxicitypreventableandtreatable |